NO20064792L - Use of rotigotine for the treatment and connection of Parkinson's plus syndrome. - Google Patents
Use of rotigotine for the treatment and connection of Parkinson's plus syndrome.Info
- Publication number
- NO20064792L NO20064792L NO20064792A NO20064792A NO20064792L NO 20064792 L NO20064792 L NO 20064792L NO 20064792 A NO20064792 A NO 20064792A NO 20064792 A NO20064792 A NO 20064792A NO 20064792 L NO20064792 L NO 20064792L
- Authority
- NO
- Norway
- Prior art keywords
- rotigotine
- parkinson
- treatment
- connection
- plus syndrome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the use of rotigotine, its salts and prodrugs, as a medicament for preventing and/or treating Parkinson's plus syndrome.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004014841A DE102004014841B4 (en) | 2004-03-24 | 2004-03-24 | Use of rotigotine for the treatment and prevention of Parkinson-Plus syndrome |
PCT/EP2005/003013 WO2005092331A1 (en) | 2004-03-24 | 2005-03-22 | Use of rotigotine for treating and preventing parkinson's plus syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20064792L true NO20064792L (en) | 2006-10-23 |
Family
ID=34963175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20064792A NO20064792L (en) | 2004-03-24 | 2006-10-23 | Use of rotigotine for the treatment and connection of Parkinson's plus syndrome. |
Country Status (17)
Country | Link |
---|---|
US (1) | US7872041B2 (en) |
EP (1) | EP1727539B1 (en) |
JP (1) | JP4801042B2 (en) |
KR (1) | KR101140452B1 (en) |
CN (1) | CN100581542C (en) |
AT (1) | ATE376828T1 (en) |
AU (1) | AU2005226911B2 (en) |
CA (1) | CA2559683C (en) |
DE (2) | DE102004014841B4 (en) |
EA (1) | EA011278B1 (en) |
ES (1) | ES2296156T3 (en) |
HK (1) | HK1100765A1 (en) |
MX (1) | MXPA06010747A (en) |
NO (1) | NO20064792L (en) |
NZ (1) | NZ550025A (en) |
UA (1) | UA85583C2 (en) |
WO (1) | WO2005092331A1 (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19814084B4 (en) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation |
DE10041479A1 (en) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | New pharmaceutical composition for the administration of N-0923 |
US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
DE10234673B4 (en) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Hot-melt TTS for the administration of rotigotine and process for its preparation, and use of rotigotine in the manufacture of a hot-melt TTS |
US8246979B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
DE10261696A1 (en) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Device for the transdermal administration of rotigotine base |
DE10334188B4 (en) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Use of rotigotine to treat depression |
DE10359528A1 (en) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S) -2-N-propylamino-5-hydroxytetralin as a D3 agonist therapeutic |
DE10361258A1 (en) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Use of substituted 2-aminotetralins for the preventive treatment of Parkinson's disease |
DE10361259A1 (en) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Use of Rotigotine in Early Stage Parkinson's Disease to Prevent Further Neuronal Loss |
US20050197385A1 (en) * | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
TWI392670B (en) * | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | Use of substituted 2-aminotetralines for the manufacture of a medicament for the prevention, alleviation and/or treatment of various types of pain |
EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
US8505540B2 (en) | 2007-11-13 | 2013-08-13 | Apnicure, Inc. | Methods and systems for improving airway patency |
MX2010005925A (en) | 2007-11-28 | 2010-08-02 | Ucb Pharma Gmbh | Novel polymorphic form of rotigotine and process for production. |
EP2201941A1 (en) | 2008-12-29 | 2010-06-30 | UCB Pharma GmbH | Plaster production technology |
EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
EA025584B1 (en) | 2009-12-22 | 2017-01-30 | ЮСиБи ФАРМА ГМБХ | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
US8729306B2 (en) | 2010-02-05 | 2014-05-20 | Ucb Pharma Gmbh | Process for the preparation of nitrogen substituted aminotetralins derivatives |
KR20130122721A (en) | 2010-06-25 | 2013-11-08 | 유씨비 파르마 게엠베하 | Processes for the resolution of nitrogen substituted (s)-5-alkoxy-2-aminotetralin derivatives |
US8979823B2 (en) | 2011-02-09 | 2015-03-17 | Apnicure, Inc. | Saliva management system with continuous flow through oral device |
EP2559435A1 (en) | 2011-08-19 | 2013-02-20 | UCB Pharma GmbH | Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke |
US8383093B1 (en) | 2011-11-01 | 2013-02-26 | Serina Therapeutics, Inc. | Subcutaneous delivery of poly(oxazoline) conjugates |
DE102012013439A1 (en) | 2012-07-03 | 2014-01-23 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermal therapeutic system useful for treatment, alleviation and/or prophylaxis of e.g. Parkinson disease, depression and restless syndrome, comprises backing layer, matrix layer comprising rotigotin and protective film |
WO2013075823A1 (en) | 2011-11-22 | 2013-05-30 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermal therapeutic system comprising rotigotine and crystallization inhibitor |
DE102012013421A1 (en) | 2012-07-03 | 2014-01-09 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermal therapeutic system useful for treating, alleviating and/or preventing e.g. Parkinson's disease, depression, comprises backing layer, matrix layer comprising rotigotine, and protection film applied to part of matrix layer surface |
TW201431570A (en) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | Multi-day patch for the transdermal administration of rotigotine |
WO2015001012A1 (en) | 2013-07-03 | 2015-01-08 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system with electronic component |
EP3145503A1 (en) | 2014-05-20 | 2017-03-29 | LTS Lohmann Therapie-Systeme AG | Method for adjusting the release of active agent in a transdermal delivery system |
US11752110B2 (en) | 2014-05-20 | 2023-09-12 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
WO2015177204A1 (en) | 2014-05-20 | 2015-11-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system containing rotigotine |
US9956201B2 (en) | 2014-07-21 | 2018-05-01 | Spriaso Llc | Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms |
ES2966170T3 (en) | 2020-01-24 | 2024-04-18 | Luye Pharma Switzerland Ag | Transdermal therapeutic system comprising rotigotine and at least one non-amine resistant silicone adhesive |
FR3106978B1 (en) | 2020-02-11 | 2024-04-26 | Olivier Petitjean | USE OF A MOLECULE INHIBITING THE PRODUCTION OF ROS OF MITOCHONDRIAL ORIGIN SUCH AS ANETHOLE TRITHIONE TO TREAT PARKINSON'S DISEASE |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH649300A5 (en) | 1981-08-07 | 1985-05-15 | Sandoz Ag | ERGOPEPTIN DERIVATIVES, THEIR PRODUCTION AND USE. |
US4564628A (en) | 1983-01-03 | 1986-01-14 | Nelson Research & Development Co. | Substituted 2-aminotetralins |
US5177112A (en) | 1983-01-03 | 1993-01-05 | Whitby Research, Inc. | Substituted 2-aminotetralins |
US4722933A (en) | 1985-12-20 | 1988-02-02 | Nelson Research & Development Co. | Substituted 2-aminotetralins |
DE3479314D1 (en) * | 1984-05-22 | 1989-09-14 | Nelson Res & Dev | Substituted 2-aminotetralins and processes for synthesis |
US4885308A (en) * | 1984-08-13 | 1989-12-05 | Nelson Research & Development Co. | Method and compositions for treatment of parkinsonism syndrome in mammals |
GB8712073D0 (en) | 1987-05-21 | 1987-06-24 | Smith Kline French Lab | Medicament |
DE3868866D1 (en) | 1987-11-20 | 1992-04-09 | Erba Carlo Spa | ERGOL DERIVATIVES WITH ANTIPARKINE EFFECT. |
DE3827561C1 (en) | 1988-08-13 | 1989-12-28 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
US5234945A (en) | 1989-05-09 | 1993-08-10 | Whitby Research, Inc. | Method of producing body weight and food intake using a dopamine D2 receptor agonist |
US5545755A (en) | 1989-05-31 | 1996-08-13 | The Upjohn Company | Therapeutically useful 2-aminotetralin derivatives |
ATE172712T1 (en) | 1989-05-31 | 1998-11-15 | Upjohn Co | CNS-ACTIVE 8-HETEROCYCLYL-2-AMINOTETRALIN DERIVATIVES |
US5486611A (en) | 1989-07-13 | 1996-01-23 | The Upjohn Company | Carboxamido-(1,2N)-carbocyclic-2-aminotetralin derivatives |
US5071875A (en) | 1989-09-25 | 1991-12-10 | Northwestern University | Substituted 2-amidotetralins as melatonin agonists and antagonists |
US5151446A (en) | 1989-09-25 | 1992-09-29 | Northwestern University | Substituted 2-amidotetralins as melatonin agonists and antagonists |
US5633376A (en) | 1990-12-28 | 1997-05-27 | Neurogen Corporation | Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands |
US5681956A (en) | 1990-12-28 | 1997-10-28 | Neurogen Corporation | 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands |
WO1993000313A2 (en) | 1991-06-27 | 1993-01-07 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
DK55192D0 (en) | 1992-04-28 | 1992-04-28 | Lundbeck & Co As H | 1-piperazino-1,2-dihydroindene derivatives |
SE9301732D0 (en) | 1993-05-18 | 1993-05-18 | Haakan Wilhelm Wikstroem | NEW CENTRALLY ACTING 5-, 6-, 7-, AND 8-SUBSTITUTED SULPHONE ESTERS OF N-MONOSUBSTITUTED 2-AMINOTETRALINS |
US5382596A (en) | 1993-08-05 | 1995-01-17 | Whitby Research, Inc. | Substituted 2-aminotetralins |
TW280819B (en) | 1993-11-17 | 1996-07-11 | Sumitomo Pharma | |
GB9324018D0 (en) | 1993-11-23 | 1994-01-12 | Merck Sharp & Dohme | Therapeutic agents |
IT1276522B1 (en) * | 1995-04-07 | 1997-10-31 | Elena Benincasa | USE OF ZOLPIDEM FOR THE THERAPEUDIC TREATMENT OF NEUROPSYCHIATRIC SYNDROMES ASSOCIATED WITH DYSFUNSION AND NEURAL CIRCUITS OF |
US5891461A (en) | 1995-09-14 | 1999-04-06 | Cygnus, Inc. | Transdermal administration of olanzapine |
US5807570A (en) | 1995-09-29 | 1998-09-15 | Cygnus, Inc. | Transdermal administration of ropinirole and analogs thereof |
AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US6010877A (en) | 1997-01-10 | 2000-01-04 | Smithkline Beecham Corporation | cDNA clone HE8CS41 that encodes a novel 7-transmembrane receptor |
US6001861A (en) | 1998-01-16 | 1999-12-14 | Pharmacia & Upjohn Company | Use of pramipexole in the treatment of restless legs syndrome |
US6221627B1 (en) | 1997-02-24 | 2001-04-24 | Smithkline Beecham Corporation | cDNA clone HDPB130 that encodes a novel human 7-transmembrane receptor |
US6242572B1 (en) | 1997-05-13 | 2001-06-05 | Smithkline Beecham Corporation | Human G protein coupled lysophosphatidic acid receptor |
IT1292155B1 (en) | 1997-06-13 | 1999-01-25 | Zambon Spa | NAFTOTHIAZOLONIC DERIVATIVES ACTIVE ON THE DOPAMINERGIC RECEPTOR D 3 |
DE19814084B4 (en) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation |
ATE255888T1 (en) * | 1998-06-01 | 2003-12-15 | Ortho Mcneil Pharm Inc | TETRAHYDRONAPHTALENE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
ES2255280T3 (en) | 1998-07-03 | 2006-06-16 | Innogenetics N.V. | DIFFERENTIAL DIAGNOSIS OF THE NEURODEGENERATION. |
GB9815618D0 (en) | 1998-07-18 | 1998-09-16 | Univ Manchester | Treatment of dyskinesia |
CO5111024A1 (en) | 1998-12-29 | 2001-12-26 | Kimberly Clark Co | COMPOSITIONS OF POLYMER COATINGS TRIPPED BY ION ON WATER SENSITIVE POLYMER FILMS |
EP1232152B1 (en) | 1999-11-23 | 2004-02-04 | Aderis Pharmaceuticals, Inc. | Improved process for preparing nitrogen-substituted aminotetralins |
US20020110585A1 (en) | 1999-11-30 | 2002-08-15 | Godbey Kristin J. | Patch therapeutic agent delivery device having texturized backing |
US6227875B1 (en) | 1999-12-27 | 2001-05-08 | Hon Hai Precision Ind. Co., Ltd. | Connector assembly for vertically mounted hard disk drive |
PE20011074A1 (en) | 2000-02-23 | 2001-10-04 | Upjohn Co | USE OF PRAMIPEXOL IN THE TREATMENT OF ADDICTION DISORDERS |
DE10041479A1 (en) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | New pharmaceutical composition for the administration of N-0923 |
DE10041478A1 (en) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | New pharmaceutical composition |
AUPQ969800A0 (en) | 2000-08-28 | 2000-09-21 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
EP1332363A4 (en) | 2000-10-09 | 2007-08-29 | Kay Double | Detection of neurodegenerative disorders |
DE10055742B4 (en) | 2000-11-10 | 2006-05-11 | Schwarz Pharma Ag | New polyesters, processes for their preparation and depot dosage forms prepared from the polyesters |
US20030027793A1 (en) | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
PT1256339E (en) | 2001-05-08 | 2004-02-27 | Lohmann Therapie Syst Lts | TRANSDERMIC THERAPEUTIC SYSTEM FOR PARKINSON'S DISEASE INDUCING HIGH PLASMATIC NORMS OF ROTIGOTINE |
ES2203563T3 (en) | 2001-05-08 | 2004-04-16 | Schwarz Pharma Ag | IMPROVED TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TREATMENT OF PARKINSON'S DISEASE. |
US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
CA2493718A1 (en) | 2001-07-20 | 2003-01-30 | Paul F. Good | Methods for diagnosing and treating alzheimer's disease and parkinson's disease |
FR2828212B1 (en) | 2001-08-03 | 2003-10-31 | Aventis Pharma Sa | METHODS OF DIAGNOSING AND PROGNOSING PARKINSON'S DISEASE |
FR2829028B1 (en) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | COMBINATION OF AN ANTAGONIST OF THE CB1 RECEPTOR AND A PRODUCT THAT ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE FOR THE TREATMENT OF DISEASE |
DE10148233A1 (en) | 2001-09-28 | 2003-04-10 | Boehringer Ingelheim Pharma | Compounds to reduce excessive food intake |
HU227543B1 (en) | 2001-09-28 | 2011-08-29 | Richter Gedeon Nyrt | N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them |
PT2942082T (en) | 2002-01-28 | 2019-06-06 | Kyowa Hakko Kogyo Kk | A2a receptor antogonists for use in the treatment of movement disorders |
GB0203446D0 (en) | 2002-02-14 | 2002-04-03 | Univ Lancaster | Detection and/or monitoring of synuclein-related diseases |
WO2003076658A2 (en) | 2002-03-08 | 2003-09-18 | Decode Genetics Ehf. | A susceptibility gene for late-onset idiopathic parkinson's disease |
US20060263419A1 (en) | 2002-03-12 | 2006-11-23 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
WO2003088958A2 (en) | 2002-04-18 | 2003-10-30 | Pharmacia Corporation | Combinations of cox-2 inhibitors and other agents for the treatment of parkinson’s disease |
US20040048779A1 (en) | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
US8211462B2 (en) | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
EP1386604A1 (en) | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system |
US8246980B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
EP1386605A1 (en) | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system for the administration of rotigotine |
DE10234673B4 (en) | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Hot-melt TTS for the administration of rotigotine and process for its preparation, and use of rotigotine in the manufacture of a hot-melt TTS |
ES2239196T3 (en) | 2002-12-02 | 2005-09-16 | Schwarz Pharma Ag | IONTOPHORETIC SUPPLY OF ROTIGOTINE FOR THE TREATMENT OF PARKINSON'S DISEASE. |
DE10261696A1 (en) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Device for the transdermal administration of rotigotine base |
DE10334188B4 (en) | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Use of rotigotine to treat depression |
DE10334187A1 (en) | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituted 2-aminotetralins for the treatment of depression |
DE10359528A1 (en) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S) -2-N-propylamino-5-hydroxytetralin as a D3 agonist therapeutic |
EP1547592A1 (en) | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
DE10361258A1 (en) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Use of substituted 2-aminotetralins for the preventive treatment of Parkinson's disease |
DE10361259A1 (en) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Use of Rotigotine in Early Stage Parkinson's Disease to Prevent Further Neuronal Loss |
EP1708706A1 (en) * | 2004-01-22 | 2006-10-11 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist |
US20050197385A1 (en) | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
BRPI0514015A (en) | 2004-08-02 | 2008-05-27 | Sanol Arznei Schwarz Gmbh | indolizine carboxamides and their derivatives aza and diaza |
JP2008514376A (en) | 2004-09-29 | 2008-05-08 | シュウォーツ ファーマ インコーポレイテッド | Transdermal therapeutic system for Parkinson's disease |
DE102004054634A1 (en) | 2004-11-12 | 2006-05-18 | Schwarz Pharma Ag | Azaindolcarboxamide |
TWI392670B (en) | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | Use of substituted 2-aminotetralines for the manufacture of a medicament for the prevention, alleviation and/or treatment of various types of pain |
EP1987815A1 (en) | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
MX2010005925A (en) | 2007-11-28 | 2010-08-02 | Ucb Pharma Gmbh | Novel polymorphic form of rotigotine and process for production. |
-
2004
- 2004-03-24 DE DE102004014841A patent/DE102004014841B4/en not_active Expired - Fee Related
-
2005
- 2005-03-22 MX MXPA06010747A patent/MXPA06010747A/en active IP Right Grant
- 2005-03-22 US US10/593,964 patent/US7872041B2/en not_active Expired - Fee Related
- 2005-03-22 WO PCT/EP2005/003013 patent/WO2005092331A1/en active IP Right Grant
- 2005-03-22 CA CA2559683A patent/CA2559683C/en not_active Expired - Fee Related
- 2005-03-22 AT AT05728686T patent/ATE376828T1/en not_active IP Right Cessation
- 2005-03-22 EP EP05728686A patent/EP1727539B1/en active Active
- 2005-03-22 JP JP2007504337A patent/JP4801042B2/en not_active Expired - Fee Related
- 2005-03-22 CN CN200580009165A patent/CN100581542C/en not_active Expired - Fee Related
- 2005-03-22 NZ NZ550025A patent/NZ550025A/en not_active IP Right Cessation
- 2005-03-22 UA UAA200609686A patent/UA85583C2/en unknown
- 2005-03-22 ES ES05728686T patent/ES2296156T3/en active Active
- 2005-03-22 KR KR1020067021135A patent/KR101140452B1/en not_active IP Right Cessation
- 2005-03-22 DE DE502005001828T patent/DE502005001828D1/en active Active
- 2005-03-22 AU AU2005226911A patent/AU2005226911B2/en not_active Ceased
- 2005-03-22 EA EA200601746A patent/EA011278B1/en not_active IP Right Cessation
-
2006
- 2006-10-23 NO NO20064792A patent/NO20064792L/en not_active Application Discontinuation
-
2007
- 2007-06-05 HK HK07105904A patent/HK1100765A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2005226911B2 (en) | 2011-02-10 |
EP1727539B1 (en) | 2007-10-31 |
CA2559683A1 (en) | 2005-10-06 |
DE102004014841A1 (en) | 2005-10-13 |
NZ550025A (en) | 2010-07-30 |
JP2007530484A (en) | 2007-11-01 |
EA200601746A1 (en) | 2007-04-27 |
DE502005001828D1 (en) | 2007-12-13 |
MXPA06010747A (en) | 2006-12-15 |
UA85583C2 (en) | 2009-02-10 |
CN100581542C (en) | 2010-01-20 |
AU2005226911A1 (en) | 2005-10-06 |
KR101140452B1 (en) | 2012-04-30 |
EP1727539A1 (en) | 2006-12-06 |
DE102004014841B4 (en) | 2006-07-06 |
KR20060130730A (en) | 2006-12-19 |
ATE376828T1 (en) | 2007-11-15 |
US20070191470A1 (en) | 2007-08-16 |
JP4801042B2 (en) | 2011-10-26 |
US7872041B2 (en) | 2011-01-18 |
EA011278B1 (en) | 2009-02-27 |
WO2005092331A1 (en) | 2005-10-06 |
HK1100765A1 (en) | 2007-09-28 |
CN1960724A (en) | 2007-05-09 |
ES2296156T3 (en) | 2008-04-16 |
CA2559683C (en) | 2012-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20064792L (en) | Use of rotigotine for the treatment and connection of Parkinson's plus syndrome. | |
ATE534378T1 (en) | TITRATION OF TAPENTADOL | |
HK1125040A1 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression | |
WO2007112014A3 (en) | New therapeutic combinations for the treatment of depression | |
TW200602048A (en) | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of β -secretase | |
TW200602324A (en) | Tetrahydro-indazole cannabinoid modulators cross reference to related applications | |
RS52874B (en) | Thiophene analogues for the treatment or prevention of flavivirus infections | |
EA200900023A1 (en) | USE OF SUBSTITUTED 2-AMINOTHETRALINES FOR THE PRODUCTION OF MEDICINES FOR THE PREVENTION, FACILITATION AND / OR TREATMENT OF DIFFERENT KINDS OF PAIN | |
MX2010006823A (en) | Methods for the treatment of gout. | |
HK1141231A1 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of migraine | |
UA96592C2 (en) | Indolopyridines as eg5 kinesin modulators | |
ATE540690T1 (en) | INSULIN COMBINATIONS | |
MX2007006082A (en) | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin. | |
WO2008090287A3 (en) | Use of at least one botulism neurotoxin for treating the pain induced by therapeutic treatments for the aids virus | |
CY1114760T1 (en) | Atherosclerosis Therapeutic Treatment | |
NO20076405L (en) | Use of 24-nor-UDCA | |
MX2009004770A (en) | Carbamate compounds for use in treating depression. | |
TW200503676A (en) | Use of kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | |
WO2007095609A3 (en) | Use of benzo-heteroaryl sulfamide derivatives for the treatment of mania and bipolar disorder | |
WO2007095611A3 (en) | Use of benzo-fused heteroaryl sulfamide derivatives for the treatment of migraine | |
MX2007007183A (en) | Amines, combination of amines and vanadium and amine vanadium salts for the treatment or prevention of dyslipidemia. | |
UA85187C2 (en) | 2-aminobenzoyl derivatives | |
TW200603791A (en) | Compounds and compositions as cathepsin S inhibitors | |
EA201000738A1 (en) | MEDICAL INDICATION 3- (2,2,2-TRIMETHYLGYDRAZINIUM) PROPIONATE GYDROFUMATE AND DIGITROPHOSPHATE | |
TW200508196A (en) | Hydroxamic acids useful in the treatment of hyper-proliferative disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |